Sector: Consumer Non-Cyclicals | Industry: Food Processing |
Company Contact | |
Address: | Suite 300, 1055 West Hastings St VANCOUVER BC V6E 2E9 |
Tel: | N/A |
Website: | https://genixpharm.com |
IR: | See website |
Key People | ||
Mahmoud S. Aziz President, Director | Sina Salehi Pirooz Chief Executive Officer, Director | Danny Lee Chief Financial Officer |
Business Overview |
Genix Pharmaceuticals Corporation is a nutraceutical and generic ophthalmic drugs company. The Company is focused on the research, development, manufacturing, licensing, and sales of healthcare products. Its products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single-molecule generic drugs. The Company is engaged in marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Bimatoprost 0.01% Eye Drops, Timolol 0.5% Eye Drops, Loteprednol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Brimonidine 0.2% Eye Drops. The Company sells its ophthalmic products through traditional pharmacy and drugstore retail outlets and as well as direct to consumers and e-commerce platforms. |
Financial Overview |
For the three months ended 31 January 2024, Genix Pharmaceuticals Corp revenues decreased from C$2K to C$0K. Net loss decreased 74% to C$59K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Consulting and management fees decrease of 74% to C$15K (expense), Foreign exchange gain (loss) increase of 69% to C$12K (income). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $4.62M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.01M as of Jan 31, 2024 |
EBITDA (TTM): | -$0.29M as of Jan 31, 2024 |
Net annual income (TTM): | -$4.23M as of Jan 31, 2024 |
Free cash flow (TTM): | -$0.21M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | $1.14M as of Jan 31, 2024 |
Shares outstanding: | 59,224,131 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |